Articles tagged with: Stem Cell Transplant
Today was the second day of the American Society of Clinical Oncology (ASCO) annual meeting. Although the day has not been as busy with myeloma-related presentations as tomorrow and Monday will be, there still were some interesting presentations and discussions.
The Beacon published an update earlier today with news from a morning poster session that featured several presentations related to multiple myeloma (see related Beacon news).
This article covers material from an early-afternoon education session that was titled: ”Controversies in Myeloma: Induction, Transplant, and Maintenance.”
The education session included three …
Multiple myeloma patients receiving an infusion of their own stem cells either one day or two days after undergoing treatment with high-dose melphalan demonstrate similar clinical outcomes, according to a recent U.S. study.
The study investigators conclude that a day of rest between treatment with melphalan and stem cell infusion appears not to be necessary. Based on their findings, they recommend that melphalan administration the day before stem cell infusion should be considered as standard of care.
According to Dr. Giampaolo Talamo of the Penn State Hershey Cancer Institute in …
As you may remember from my previous column, I was admitted to the hospital for my stem cell transplant at the beginning of March (on March 5 to be exact).
I had no initial devastating reaction to the melphalan (Alkeran) that I received on the day of admission or the infusion of my stem cells over the following two days.
While my first 10 to 11 days were certainly not pleasant, they weren’t “off the charts” bad either. For the first week, I was allowed to walk in …
The results of a recent analysis suggest that the dosage of re-infused lymphocytes during an autologous stem cell transplant does not affect relapse or survival rates in newly diagnosed multiple myeloma patients.
“These findings would seem to indicate that, in the context of upfront autologous stem cell transplantation, the proportion of the lymphocytes re-infused is not associated with outcome. In the salvage setting, further analysis needs to be done,” said Dr. Laura Percy of University College London and lead investigator of the study.
High-dose chemotherapy followed by autologous stem cell …
The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago.
More than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Collaborating to Conquer Cancer.”
The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists nearly 50 myeloma-based presentations (included under “lymphoma and plasma cell …